Dimensional Fund Advisors Ltd. : Form 8.3 - Galliford Try

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
27
Dimensional Fund Advisors Ltd. : Form 8.3 - Galliford Try Plc - Ordinary shares

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")

1.         KEY INFORMATION

(a) Full name of discloser:   Dimensional Fund Advisors Ltd. ("Dimensional"), in its capacity as investment manager and on behalf its affiliates who are also investment managers. Dimensional and its affiliates expressly disclaim beneficial ownership of the shares described in this form 8.3
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):      The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.    
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:      Use a separate form for each offeror/offeree   Galliford Try Plc (GB00B3Y2J508)
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:    
(e) Date position held/dealing undertaken:      For an opening position disclosure, state the latest practicable date prior to the disclosure   23 March 2017
(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?      If it is a cash offer or possible cash offer, state "N/A"   YES If YES, specify which:   Bovis Homes Group Plc (GB0001859296)   Redrow Plc (GB0007282386)

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:     50p Ordinary Shares
      Interests   Short positions
  Number   %   Number   %
(1) Relevant securities owned and/or controlled:   3,338,886*   4.03        
(2) Cash-settled derivatives:                  
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:                
                                                                                             TOTAL:   3,338,886   4.03        

*Dimensional Fund Advisors Ltd. and / or its affiliates do not control voting discretion for 175,656 shares

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)        Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists:    
Details, including nature of the rights concerned and relevant percentages:    

3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security   Purchase/sale     Number of securities   Price per unit
Ordinary shares   Sale   4,686   GBP 15.3575

(b)        Cash-settled derivative transactions

Class of relevant security   Product description e.g. CFD   Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position   Number of reference securities   Price per unit
                 

(c)        Stock-settled derivative transactions (including options)

(i)         Writing, selling, purchasing or varying

Class of relevant security   Product description e.g. call option   Writing, purchasing, selling, varying etc.   Number of securities to which option relates   Exercise price per unit   Type e.g. American, European etc.   Expiry date   Option money paid/ received per unit
                             

(ii)        Exercise

Class of relevant security   Product description e.g. call option   Exercising/ exercised against   Number of securities   Exercise price per unit
                 

(d)        Other dealings (including subscribing for new securities)

Class of relevant security   Nature of dealing e.g. subscription, conversion   Details   Price per unit (if applicable)
             

4.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"
     

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"
     

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?   NO
Date of disclosure:   24 March 2017
Contact name:   Thomas Hone
Telephone number:   020 3033 3419

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Segway Powersports Ventures into Baja 1000: Ambitions Run High

Updated Category News Views 133

They're gunning for glory in the sands of Baja, folks—Segway Powersports is about to rev up the excitement with its Baja 1000 debut. Never heard before in this legendary race's chronicles, Segway aims to shake up the game with their two brawny Super Villain UTVs. These aren't your run-of-the-pavement ride-ons; they're built for the rough stuff—and if there's a stage...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 353

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 189

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 386

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 694

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 234

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 226

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 475

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
UAE Pioneers eATA Carnet System Beyond Europe

Updated Category News Views 139

Breaking Tradition with Digital Innovation Well, who would’ve thought? The UAE just leapt ahead in the trade game, becoming the first to roll out the eATA Carnet system beyond the cozy confines of Europe. This isn’t some run-of-the-mill tech rollout, folks. It’s a digital revolution in how temporary imports are handled—goodbye paper, hello efficiency! With this...

Continue Reading
Nutex Health Scores Top Workplace Honor in 2026

Updated Category News Views 43

Nutex Health: Accolades and Aspirations Nutex Health just snagged something pretty noteworthy: They've been crowned a 2026 Houston Top Workplace by the Houston Chronicle. Now, before you start throwing confetti, let's chew on what this really means. It's no small potatoes, folks. We're talking employee respect and satisfaction measured by Energage’s surveys. It's proof...

Continue Reading

Top 5 Most Recently Viewed Articles

Orla Mining's Earnings Predictions and Market Insights

Updated Category News Views 537

Anticipated Earnings Release for Orla Mining Orla Mining (AMEX: ORLA) is set to unveil its quarterly earnings, and investors are keenly observing the upcoming report. Analysts are projecting the company will announce an earnings per share (EPS) of $0.20, which generates a mix of anticipation and excitement in the market. Insights Into Previous Earnings Performance In the...

Continue Reading
Bar Leone Reigns Supreme as Asia's Best Bar Again

Updated Category News Views 209

Bar Leone Recognized as Asia's Leading Bar for Two Years Bar Leone has once again captured the prestigious title of The Best Bar in Asia, an accolade it earned for the second consecutive year at the Asia's 50 Best Bars ceremony. This recognition, sponsored by Perrier, marks a significant milestone in the vibrant cocktail culture across the continent. Outstanding...

Continue Reading
Commvault Faces Securities Fraud Lawsuit: What's Next?

Updated Category News Views 36

Unpacking Commvault's Legal Headaches There's fresh trouble brewing in the world of Commvault Systems Inc. (NASDAQ: CVLT). Investors licking their wounds have a chance to rally in a securities fraud class action lawsuit. It all circles back to some allegedly shady moves—or, more precisely, what the company didn't spill between April 2025 and January 2026. The Crux of...

Continue Reading
Investigating Lumos Pharma's Acquisition: Implications for Shareholders

Updated Category News Views 76

Investigation into Lumos Pharma's Proposed Acquisition Rowley Law PLLC is currently looking into potential securities law violations related to Lumos Pharma, Inc. (NASDAQ: LUMO). This investigation centers around the proposed acquisition of Lumos Pharma by Double Point Ventures LLC. Under the terms of this acquisition, shareholders are set to receive $4.25 along with one...

Continue Reading
LKQ Faces Investor Suit: Key Impacts & Deadlines

Updated Category News Views 17

LKQ's Acquisition Missteps Ignite Investor Action Just when you think you've seen it all in the stock market, something like this drops—another punch in the gut reminding us that no company is impervious to stumbling. LKQ Corporation (NASDAQ: LKQ) has got itself tangled in some messy legal affairs, thanks to a string of ugly truths coming to light from its pricey $2.1...

Continue Reading